이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

소아의 약물 감수성 결핵에 대한 단축 요법 (SMILE-TB)

2026년 11월 6일 업데이트: Johns Hopkins University

While drug-susceptible tuberculosis (TB) disease in children currently requires four to six months of treatment, most children may be able to be cured with a shorter treatment of more powerful drugs. Shorter treatment may be easier for children to tolerate and finish as well as ease caregiver strain from managing treatment side effects and supporting children over many months. The primary objective of this study is to evaluate if a 2-month regimen (including isoniazid (H), rifapentine (P), pyrazinamide (Z) and moxifloxacin (M)) is as safe and effective as a 4- to 6-month regimen (isoniazid, rifampicin (R), pyrazinamide, ethambutol (E)) in curing drug-susceptible TB disease in children under 10 years old. The study is also evaluating the safety of the HPZM in children with and without HIV.

연구 개요

상태

모병

정황

개입 / 치료

상세 설명

In previously untreated individuals with presumed drug-susceptible pulmonary and or peripheral lymph node TB treated with eight weeks of rifapentine, isoniazid, pyrazinamide and moxifloxacin (2HPZM), all given daily throughout, the proportion of participants who experience absence of cure (unsuccessful outcome) will not be inferior to that observed in participants who are treated with the standard regimen (eight weeks of rifampin, isoniazid, pyrazinamide, with or without ethambutol followed by 8 to 16 weeks of rifampin plus isoniazid depending on disease severity) all given daily throughout.

연구 유형

중재적

등록 (추정된)

860

단계

  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

  • 이름: Kisten Nolan, MPH, BSN
  • 전화번호: +14435403993
  • 이메일: knolan2@jh.edu

연구 장소

      • Durban, 남아프리카
        • 모병
        • Africa Health Research Institute (AHRI)
        • 수석 연구원:
          • Moherndran Archary, MBChB, PhD
        • 연락하다:
      • Maputo, 모잠비크
        • 모병
        • Instituto Nacional de Saúde (INS)
        • 연락하다:
        • 수석 연구원:
          • Celso Khosa, MD, PhD
      • Kampala, 우간다
        • 모병
        • MU-JHU Care Ltd
        • 연락하다:
        • 수석 연구원:
          • Eric Wobudeya, MBChB MMed MSc
      • Chennai, 인도
        • 모병
        • Indian Council of Medical Research - National Institute for Research in Tuberculosis
        • 연락하다:
        • 수석 연구원:
          • Aishwarya Venkataraman, MBBS, DCH, PgDip PID, MRCPCH
      • Pune, 인도
        • 모병
        • Dr. D.Y. Patil Medical College, Hospital and Research Center
        • 연락하다:
        • 수석 연구원:
          • Shailaja Mane, MBBS, MD, PGDAP, FRIPH
      • Bandung, 인도네시아
        • 모병
        • Faculty of Medicine, Universitas Padjadjaran
        • 연락하다:
        • 수석 연구원:
          • Rovina Ruslami, MD, PhD
      • Lusaka, 잠비아
        • 모병
        • University of Zambia, School of Medicine
        • 연락하다:
          • Chishala Chabala, MBChB MMed MSc
          • 전화번호: +260977849537
          • 이메일: cchabala@gmail.com
        • 수석 연구원:
          • Chishala Chabala, MBChB MMed MSc
      • Ndola, 잠비아
        • 모병
        • Arthur Davison Children's Hospital
        • 연락하다:
      • Harare, 짐바브웨
        • 모병
        • Harare Health and Research Consortium (HHRC)
        • 연락하다:
        • 수석 연구원:
          • Mutsa Bwakura-Dangarembizi, MBChB, MMed (Paeds)

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

1초 (어린이)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Parent or guardian is willing and able to provide written informed consent for potential participant's study participation; in addition, when applicable per Ethics Committee/Institutional Review Board (EC/IRB) policies and procedures, potential participant is willing and able to provide assent for study participation.

  • At Entry, age of less than 10 years.

  • At Entry, weight 3 kilograms (kg) or greater.

  • At Entry, diagnosed with TB disease, defined as:

    • Pulmonary (including pleural effusion) and/or lymph node (extra-thoracic and/or intra-thoracic) TB with or without bacteriologic confirmation;
    • Clinician has decided to treat with standard first-line drug-susceptible TB regimen.
  • Known HIV status or HIV testing in progress based on meeting testing requirements.

  • Has normal, Grade 1 or 2 test results for all of the following done at or within 14 days of Entry (including the most recent):

    • Alanine aminotransferase (ALT) less than or equal to 5 times the upper limit of normal;
    • Total bilirubin less than or equal to 2.5 times the upper limit of normal;
    • Potassium level of 3.0 milliequivalent/L or greater;
    • Hemoglobin level of 7.0 g/dL or greater;
    • Platelet count of 100,000/mm3 or greater;
    • Estimated glomerular filtration rate (eGFR; bedside Schwartz formula) 60 mL/min/1.73m2 or higher.
  • For children living with HIV:

    • On antiretroviral therapy (ART) at Entry: Must be on, or able to be switched to a dolutegravir-based regimen at or prior to Entry;
    • Not on ART at Entry: Planned initiation of dolutegravir before or at study Week 4.
  • For participants who have reached menarche or who are engaging in sexual activity (self-reported): negative serum or urine pregnancy test within 7 days of Entry.

  • For participants who are engaging in sexual activity that could lead to pregnancy (self-reported): agrees to practice at least one non-hormonal method of contraception or abstain from heterosexual intercourse during study drug treatment and for 30 days after stopping study medications. Non-hormonal methods include:

    • Male or female condoms
    • Diaphragm or cervical cap (with spermicide, if available)
    • Non-hormonal intrauterine device (IUD) or intrauterine system (IUS)
  • At Entry, intends to remain in the catchment area of the study site for the duration of study follow-up or willingness to be followed up beyond the catchment area if/when applicable, as determined by the site investigator based on participant/parent/guardian report.

Exclusion Criteria:

  • Presumed or documented extra-pulmonary TB involving the central nervous system and/or bones and/or joints, and/or miliary TB, and/or pericardial TB and/or TB of the gastrointestinal (GI) tract and/or renal TB.

  • Premature infant (born less than 37-weeks gestation) who is less than 3 months of age at Entry.

  • Any known contraindication to taking any study drug:

    • Known allergy or intolerance to any of the study drugs or drugs in the same class as the study drugs;
    • Any prohibited medications within three days prior to Entry or planned use within the following 6 months;
    • Unable to take oral medications;
    • Known history of prolonged QT syndrome not caused by electrolyte derangements.
  • Received more than 10 days of treatment directed against TB disease within 6 months preceding initiation of study drugs.

  • M. tuberculosis isolate known or suspected to be resistant to isoniazid, rifampin, pyrazinamide, ethambutol, and/or fluoroquinolones.

  • Known exposure to an infectious adult with drug-resistant TB, including resistance to isoniazid, rifampin, pyrazinamide, ethambutol, and/or fluoroquinolones.

  • Has any other documented or suspected clinically significant medical condition or any other condition that, in the opinion of the site investigator, would make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.

  • Previously enrolled in this study.

Late Exclusions:

  • M. tuberculosis cultured or detected through World Health Organization (WHO) approved molecular assays (e.g., Cepheid Xpert MTB/RIF, Xpert XDR, sequencing or Hain MTB-DR plus assays) from sputum, swallowed sputum, nasopharyngeal aspirates, stool, or lymph node aspirate obtained around the time of study entry is determined to be resistant to isoniazid and/or rifampin and/or pyrazinamide and/or ethambutol and/or fluoroquinolones.
  • Any child with a clinical TB diagnosis who is found to have a definitive alternative diagnosis for their presenting signs and symptoms whose TB treatment is discontinued prior to completion.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
활성 비교기: Regimen 1: Isoniazid (H), Rifampin (R), Pyrazinamide (Z), Ethambutol (E)

8 weeks of daily HRZ(E) followed by either 16 or 24 weeks of daily HR, per local standard of care

Once daily weight-based dose

다른 이름들:
  • 시간

Once daily weight-based dose

다른 이름들:
  • 아르 자형

Once daily weight-based dose

다른 이름들:
  • 지

Once daily weight-based dose

다른 이름들:
  • 이자형
실험적: Regimen 2: Isoniazid (H), Rifapentine (P), Pyrazinamide (Z), Moxifloxacin (M)

8 weeks of daily HPZM

Once daily weight-based dose

다른 이름들:
  • 시간

Once daily weight-based dose

다른 이름들:
  • 지

Once daily weight-based dose

다른 이름들:
  • 프리틴
  • 피

Once daily weight-based dose

다른 이름들:
  • 아벨록스
  • 미디엄

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
TB disease-free survival at 48-weeks
기간: Measured from study entry through week 48

Non-inferiority will be assessed by comparing the upper bound of a 95%, 2-sided confidence interval for the difference between the proportion of participants who are classified as having an unsuccessful outcome on the control regimen (HRZ(E)) and the intervention regimen (HPZM) to the predefined non-inferiority margin of 6% at 48 weeks.

Measured from study entry through week 48
Proportion of participants with grade 3 or higher adverse events over 28 weeks
기간: Measured from study entry through Week 28

The proportion of participants with a Grade 3 or higher adverse event and the corresponding 95% confidence intervals will be generated. An exact test for equality of proportions will be used to compare safety outcomes between the arms.

Measured from study entry through Week 28

2차 결과 측정

결과 측정
측정값 설명
기간
TB disease-free survival at 48-weeks
기간: Measured from study entry through Week 48

Non-inferiority will be assessed by comparing the upper bound of a 95%, 2-sided confidence interval for the difference between the proportion of participants who are classified as having an unsuccessful outcome on the control regimen (HRZ(E)) and the intervention regimen (HPZM) to the predefined non-inferiority margin of 6% at 48 weeks.

Measured from study entry through Week 48
TB disease-free survival at 72-weeks
기간: Measured from study entry through Week 72

Non-inferiority will be assessed by comparing the upper bound of a 95%, 2-sided confidence interval for the difference between the proportion of participants who are classified as having an unsuccessful outcome on the control regimen (HRZ(E)) and the intervention regimen (HPZM) to the predefined non-inferiority margin of 6% at 72 weeks.

Measured from study entry through Week 72
Adherence to treatment regimens
기간: Measured from study entry through Week 48

The per-protocol analysis will account for variations in adherence to the treatment regimens. Inverse probability of treatment weighting (IPTW) using propensity scores will be applied and the net difference in treatment failure rates between the two treatment regimens and the 95% confidence interval around this will be calculated to determine non-inferiority.

Measured from study entry through Week 48
Tolerability as assessed by proportion of participants who discontinue treatment
기간: Week 8 (intervention/HPZM) or Week 16 or Week 24 (control/HRZ(E))

Tolerability will be assessed as discontinuation of the assigned treatment for a reason other than microbiological ineligibility (AEs assessed as related to the study regimen that led to permanent discontinuation of the regimen, participant refusal, parent/guardian prematurely discontinues, etc.) among the modified intention-to-treat population. Proportion of participants who discontinue the assigned study regimen and the corresponding 95% confidence intervals will be generated. The control regimen (HRZ(E)) will be compared against the intervention regimen (HPZM) using an exact test for equality of proportions.

Week 8 (intervention/HPZM) or Week 16 or Week 24 (control/HRZ(E))
Rifapentine Area under the curve (AUC0-24)
기간: Measured from study entry through Week 8

Area under the curve from start of dose to 24 hours post-dose. Measured at Week 4 or Week 8. Blood samples drawn at 0, 1 minute, 2 minutes, 4 hours and 6 hours post dose.

Measured from study entry through Week 8
Rifapentine minimal concentration (Cmin)
기간: Measured from study entry through Week 8

Minimal concentration from start of dose to 24 hours post-dose. Measured at Week 4 or Week 8. Blood samples drawn at 0, 1 minute, 2 minutes, 4 hours and 6 hours post dose.

Measured from study entry through Week 8
Rifapentine peak concentration (Cmax)
기간: Measured from study entry through Week 8

Peak concentration from start of dose to 24 hours post-dose. Measured at Week 4 or Week 8. Blood samples drawn at 0, 1 minute, 2 minutes, 4 hours and 6 hours post dose.

Measured from study entry through Week 8
Moxifloxacin AUC0-24
기간: Measured from study entry through Week 8

Area under the curve from start of dose to 24 hours post-dose. Measured at Week 4 or Week 8. Blood samples drawn at 0, 1 minute, 2 minutes, 4 hours and 6 hours post dose.

Measured from study entry through Week 8
Moxifloxacin Cmin
기간: Measured from study entry through Week 8

Minimal concentration from start of dose to 24 hours post-dose. Measured at Week 4 or Week 8. Blood samples drawn at 0, 1 minute, 2 minutes, 4 hours and 6 hours post dose.

Measured from study entry through Week 8
Moxifloxacin Cmax
기간: Measured from study entry through Week 8

Peak concentration from start of dose to 24 hours post-dose. Measured at Week 4 or Week 8. Blood samples drawn at 0, 1 minute, 2 minutes, 4 hours and 6 hours post dose.

Measured from study entry through Week 8
Parent/guardian and/or participant reported palatability and acceptability of study regimen
기간: Baseline, Week 4, Week 8 (Regimens 1 and 2) and at Weeks 16 and 24 (Regimen 1 only)

Based on questionnaire developed by study team, data will be aggregated to measure acceptability at Entry, Week 4, and Week 8 (all participants), and Weeks 16 and 24 (for those who continue on HRZ(E) only). Scoring based on a likert or likert-like scale for each question. Each question is scored 1 to 5 with higher scores reflecting increased acceptability.

Baseline, Week 4, Week 8 (Regimens 1 and 2) and at Weeks 16 and 24 (Regimen 1 only)
Adherence as assessed by proportion of participants who have taken at least 90% of their doses
기간: Baseline through Week 8 for HPZM, Week 16 for HRZ(E) with non-severe disease, or Week 24 for HRZ(E) with severe disease

Adherence measures will be documented by a treatment supporter on a TB treatment card (as per local practice), by pill count and by an adherence questionnaire and descriptively summarized for all participants. Participants are considered adherent who have taken at least 90% of their doses within the 8 week, 16 week or 24-week time frame of their regimen.

Baseline through Week 8 for HPZM, Week 16 for HRZ(E) with non-severe disease, or Week 24 for HRZ(E) with severe disease
Risk Stratification Algorithm
기간: Measured from study entry through Week 48

If the study outcome is not non-inferior, pragmatic, programmatically available data will be considered for inclusion in a risk stratification algorithm that would aim to identify children at high risk of unsuccessful TB treatment outcome who may benefit from a longer duration of therapy. The efficacy endpoint will be analyzed using mixed-effects logistic regression models to identify predictors. The models will be adjusted for World Bank country income categories and by site using random intercepts. Univariable and multivariable analysis will be performed. The association between baseline clinical predictors and unsuccessful treatment outcomes will be analyzed, Treatment characteristics will then be added to the models to determine if treatment helped in the description of the primary efficacy endpoint.

Measured from study entry through Week 48
Cost effectiveness as assessed by the incremental cost-effective ratio (ICER)
기간: Measured from study entry through Week 24

ICER: Total costs of HPZM minus the total costs 16 or 24 week HRZE, divided by the total number of disability-adjusted life-year (DALY) averted for HPZM minus the total DALYs averted for 16- or 24-week HRZE.

Measured from study entry through Week 24

기타 결과 측정

결과 측정
측정값 설명
기간
Dolutegravir AUC0-24
기간: Measured from study entry through Week 28

Area under the curve from start of dose to 24 hours post-dose. Measured at Week 4 or 8 and at between Weeks 12-28. Blood samples drawn at 0, 1 hour, 4 hours and 6 hours post dose.

Measured from study entry through Week 28
Dolutegravir Cmin
기간: Measured from study entry through Week 28

Minimal concentration from start of dose to 24 hours post-dose. Measured at Week 4 or 8 and at between Weeks 12-28. Blood samples drawn at 0, 1 hour, 4 hours and 6 hours post dose.

Measured from study entry through Week 28
Dolutegravir Cmax
기간: Measured from study entry through Week 28

Peak concentration from start of dose to 24 hours post-dose. Measured at Week 4 or 8 and at between Weeks 12-28. Blood samples drawn at 0, 1 hour, 4 hours and 6 hours post dose.

Measured from study entry through Week 28
Proportion of children living with HIV
기간: Week 24 and Week 48

Among participants living with HIV, the proportions of participants in each study arm who achieve or maintain virologic control (< 200 copies/mL) at Weeks 24 and 48 will be presented in aggregate, as well as broken down by weight bands (if the sample sizes are sufficient) bounded by 95% confidence intervals.

Week 24 and Week 48

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

협력자

수사관

  • 수석 연구원: Nicole Salazar-Austin, MD, ScM, Johns Hopkins University

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

일반 간행물

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2025년 1월 15일

기본 완료 (추정된)

2027년 9월 30일

연구 완료 (추정된)

2027년 9월 30일

연구 등록 날짜

최초 제출

2024년 1월 26일

QC 기준을 충족하는 최초 제출

2024년 2월 2일

처음 게시됨 (실제)

2024년 2월 12일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 12일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 6일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • IRB00388853

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

Make individual participant data, after de-identification, publicly available in accordance with USAID's policy on data sharing.

IPD 공유 기간

After study completion, de-identified data that can be legally released to the public may be released.

IPD 공유 액세스 기준

With whom: Researchers who provide a methodologically sound proposal for the use of the data per USAID's policy on data sharing and in accordance with in-country data sharing agreements.

For what types of analysis: To achieve aims specified in the researcher's approved proposal.

By what mechanisms will data be available: To be determined.

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .